Dexcom Reports First Quarter 2026 Financial Results

4/30/26 4:02:00 PM ET

$DXCM

Medical/Dental Instruments

Health Care

Get the next $DXCM alert in real time by email

DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights:

Revenue grew 15% year-over-year to $1.192 billion on a reported basis and 12% year-over-year on an organic¹ basis.
U.S. revenue grew 11% and international revenue grew 26% on a reported basis and 17% on an organic¹ basis, all on a year-over-year basis.
GAAP operating income of $255.3 million or 21.4% of revenue, an increase of 850 basis points compared to the first quarter of 2025. Non-GAAP operating income* of $264.4 million or 22.2% of reported revenue, an increase of 840 basis points compared to the first quarter of 2025.

First Quarter 2026 Strategic Highlights:

Expanded the launch of Dexcom G7 15 Day CGM across all channels in the United States.
Introduced enhanced Smart Meal Logging features to the Stelo platform.
Showcased extensive clinical evidence at ATTD 2026, including one-year registry data demonstrating that Dexcom G7 delivered significant improvement in A1C for people with type 2 diabetes who are not on insulin therapy.

"Dexcom delivered strong revenue growth and margin performance to start the year, reflecting healthy demand for Dexcom CGM and continued operational improvement," said Jake Leach, Dexcom's president and CEO. "We will work to build on this momentum throughout 2026 and look forward to highlighting Dexcom's long-term growth opportunity at our Investor Day in the coming weeks."

2026 Annual Guidance

Dexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following levels:

Revenue of $5.16 - $5.25 billion (approximately 11-13% growth)
Non-GAAP Gross Profit Margin of approximately 63-64%
Non-GAAP Operating Margin of approximately 23-23.5%
Adjusted EBITDA Margin of approximately 31-31.5%

____________________

¹ First quarter 2026 organic revenue was $1.165 billion and excludes $26.6 million of foreign exchange impact.

First Quarter 2026 Financial Results

Revenue: In the first quarter of 2026, worldwide revenue grew 15% to $1.192 billion on a reported basis, up from $1.036 billion in the first quarter of 2025.

Gross Profit: GAAP gross profit totaled $750.3 million or 62.9% of revenue for the first quarter of 2026, compared to $589.0 million or 56.9% of revenue in the first quarter of 2025.

Non-GAAP gross profit* totaled $757.4 million or 63.5% of reported revenue for the first quarter of 2026, compared to $596.2 million or 57.5% of reported revenue in the first quarter of 2025.

Operating Income: GAAP operating income for the first quarter of 2026 was $255.3 million or 21.4% of revenue, compared to GAAP operating income of $133.7 million or 12.9% of revenue for the first quarter of 2025.

Non-GAAP operating income* for the first quarter of 2026 was $264.4 million or 22.2% of reported revenue, compared to non-GAAP operating income of $143.1 million or 13.8% of reported revenue for the first quarter of 2025.

Net Income and Diluted Net Income Per Share: GAAP net income was $199.5 million, or $0.51 per diluted share, for the first quarter of 2026, compared to GAAP net income of $105.4 million, or $0.27 per diluted share, for the first quarter of 2025.

Non-GAAP net income* was $216.3 million, or $0.56 per diluted share, for the first quarter of 2026, compared to non-GAAP net income of $127.7 million, or $0.32 per diluted share, for the first quarter of 2025. The first quarter 2026 non-GAAP net income excludes $8.0 million of amortization of intangible assets, $1.1 million of business transition and other significant items, and $7.7 million of tax adjustments.

Cash and Liquidity: As of March 31, 2026, Dexcom held $2.42 billion in cash, cash equivalents and marketable securities and our revolving credit facility remains undrawn. The cash balance represents significant financial and strategic flexibility as Dexcom continues to expand production capacity and explore new market opportunities.

* See Table D below for a reconciliation of these GAAP and non-GAAP financial measures.

Conference Call

Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to "Events and Presentations," and will be archived for future reference. To listen to the conference call, please dial (888) 414-4585 (U.S./Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start time.

Statement Regarding Use of Non-GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), please see the section titled "About Non-GAAP Financial Measures" below as well as the related Table D. We have not reconciled our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin estimates for fiscal year 2026 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, reconciliations of our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin estimates are not available without unreasonable effort.

About DexCom, Inc.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

Category: IR

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that are not purely historical regarding Dexcom's or its management's intentions, beliefs, expectations and strategies for the future, including those related to Dexcom's future operating results and financial position, including estimated Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin for fiscal year 2026, and expected growth rates as compared to the year ended December 31, 2025; future expenses and investments; and potential business plans and opportunities. All forward-looking statements included in this press release are made as of the date of this press release, based on information currently available to Dexcom as of the date hereof. Forward-looking statements deal with future events and are therefore subject to various risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom's current expectations are more fully described in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Dexcom's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings filed with the Securities and Exchange Commission. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this communication or to conform these forward-looking statements to actual results.

DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) (Unaudited)
	March 31, 2026			December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$	1,118.2		$	917.7
Short-term marketable securities		1,297.0			1,081.0
Accounts receivable, net		1,088.6			1,216.1
Inventory		693.6			629.1
Prepaid and other current assets		134.3			189.4
Total current assets		4,331.7			4,033.3
Property and equipment, net		1,559.7			1,559.9
Operating lease right-of-use assets		73.1			77.4
Goodwill		24.2			24.2
Intangibles, net		62.6			70.8
Deferred tax assets		296.1			295.6
Other assets		285.9			278.7
Total assets	$	6,633.3		$	6,339.9
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities	$	2,073.9		$	1,944.0
Accrued payroll and related expenses		121.8			169.2
Short-term operating lease liabilities		20.5			21.6
Other current liabilities		7.6			7.7
Total current liabilities		2,223.8			2,142.5
Long-term senior convertible notes		1,241.8			1,240.9
Long-term operating lease liabilities		69.0			73.4
Other long-term liabilities		141.8			137.1
Total liabilities		3,676.4			3,593.9
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025		—			—
Common stock, $0.001 par value, 800.0 million shares authorized; 412.3 million and 385.9 million shares issued and outstanding, respectively, at March 31, 2026; and 410.7 million and 384.8 million shares issued and outstanding, respectively, at December 31, 2025		0.4			0.4
Additional paid-in capital		2,337.5			2,281.5
Accumulated other comprehensive income		106.2			115.0
Retained earnings		2,633.4			2,433.9
Treasury stock, at cost; 26.4 million shares at March 31, 2026 and 25.9 million shares at December 31, 2025		(2,120.6	)		(2,084.8	)
Total stockholders' equity		2,956.9			2,746.0
Total liabilities and stockholders' equity	$	6,633.3		$	6,339.9

DexCom, Inc. Table B Consolidated Statements of Operations (In millions, except per share data) (Unaudited)
	Three Months Ended March 31,
		2026		2025
Revenue	$	1,191.9	$	1,036.0
Cost of sales		441.6		447.0
Gross profit		750.3		589.0
Operating expenses:
Research and development		145.3		145.2
Selling, general and administrative		349.7		310.1
Total operating expenses		495.0		455.3
Operating income		255.3		133.7
Other income, net		14.2		20.6
Income before income taxes		269.5		154.3
Income tax expense		70.0		48.9
Net income	$	199.5	$	105.4

Basic net income per share	$	0.52	$	0.27
Shares used to compute basic net income per share		385.1		391.1
Diluted net income per share	$	0.51	$	0.27
Shares used to compute diluted net income per share		393.6		407.5

DexCom, Inc. Table C Revenue by Customer Sales Channel and Geographic Region (Dollars in millions) (Unaudited)
	Three Months Ended March 31,
	2026						2025
(In millions)	United States		International		Total		United States		International		Total
Distributor	$	796.9	$	213.4	$	1,010.3	$	720.6	$	159.4	$	880.0
Direct		35.4		146.2		181.6		29.9		126.1		156.0
Total revenue	$	832.3	$	359.6	$	1,191.9	$	750.5	$	285.5	$	1,036.0

DexCom, Inc. Table D Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures (In millions, except per share data) (Unaudited)
	Three Months Ended March 31,
		2026			2025
GAAP gross profit	$	750.3		$	589.0
Amortization of intangible assets ⁽¹⁾		7.1			7.2
Non-GAAP gross profit	$	757.4		$	596.2

GAAP operating income	$	255.3		$	133.7
Amortization of intangible assets ⁽¹⁾		8.0			7.9
Business transition and other significant items ⁽²⁾		1.1			1.0
Intellectual property litigation costs ⁽³⁾		—			0.5
Non-GAAP operating income	$	264.4		$	143.1

GAAP net income	$	199.5		$	105.4
Business transition and other significant items ⁽²⁾		1.0			1.0
Depreciation and amortization		67.1			60.0
Intellectual property litigation costs ⁽³⁾		—			0.5
Loss from equity investments		—			4.2
Share-based compensation		43.3			34.2
Interest expense and interest income		(16.4	)		(23.8	)
Income tax expense		70.0			48.9
Adjusted EBITDA	$	364.5		$	230.4

GAAP net income	$	199.5		$	105.4
Amortization of intangible assets ⁽¹⁾		8.0			7.9
Business transition and other significant items ⁽²⁾		1.1			1.0
Intellectual property litigation costs ⁽³⁾		—			0.5
Loss from equity investments		—			4.2
Adjustments related to taxes ⁽⁴⁾		7.7			8.7
Non-GAAP net income	$	216.3		$	127.7

DexCom, Inc. Table D (Continued) Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures (In millions, except per share data) (Unaudited)
	Three Months Ended March 31,
		2026			2025
GAAP net income	$	199.5		$	105.4
Interest expense on senior convertible notes, net of tax		1.6			2.9
GAAP net income used for diluted EPS, if-converted ⁽⁵⁾	$	201.1		$	108.3

Non-GAAP net income	$	216.3		$	127.7
Interest expense on senior convertible notes, net of tax		—			1.2
Non-GAAP net income used for diluted EPS, if-converted ⁽⁵⁾	$	216.3		$	128.9

GAAP diluted net income per share⁽⁵⁾	$	0.51		$	0.27
Amortization of intangible assets ⁽¹⁾		0.02			0.02
Business transition and other significant items ⁽²⁾		—			—
Intellectual property litigation costs ⁽³⁾		—			—
Loss from equity investments		—			0.01
Adjustments related to taxes ⁽⁴⁾		0.02			0.02
Impact of adjustment to GAAP diluted shares ⁽⁶⁾		0.01			—
Non-GAAP diluted net income per share ^{(5) (7)}	$	0.56		$	0.32

GAAP diluted weighted-average shares outstanding		393.6			407.5
Non-GAAP diluted weighted-average shares outstanding		385.9			399.8

Reconciliation of non-GAAP diluted weighted-average shares outstanding:
GAAP diluted weighted-average shares outstanding		393.6			407.5
Adjustment for dilutive impact of senior convertible notes due 2028 ⁽⁸⁾		(7.7	)		(7.7	)
Non-GAAP diluted weighted-average shares outstanding		385.9			399.8

		⁽¹⁾	Represents amortization of acquired intangible assets.
		⁽²⁾	For the three months ended March 31, 2026 and March 31, 2025, business transition and other significant items are primarily related to rent for vacated office space in San Diego, California.
		⁽³⁾	We have excluded third-party attorney's fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom's patent infringement litigation against Abbott Diabetes Care, Inc., as further described in the section titled "Legal Proceedings" in Dexcom's Annual Report on Form 10-K for the year ended December 31, 2024.
		⁽⁴⁾	For the three months ended March 31, 2026 and March 31, 2025, tax adjustments are primarily related to the tax effect of non-GAAP adjustments and shortfalls from share-based compensation for employees.
		⁽⁵⁾	When our senior convertible notes are dilutive on a GAAP or non-GAAP basis, net income used for calculating GAAP and non-GAAP diluted net income per share includes an interest expense add back, net of tax, under the if-converted method. In loss periods, basic and diluted net loss per share are the same since the effect of potential common shares is anti-dilutive and therefore excluded.
		⁽⁶⁾	The adjustments are for the transition from GAAP diluted net income per share to non-GAAP diluted net income per share due to our senior convertible notes.
		⁽⁷⁾	The sum of the non-GAAP per share components may not equal the totals due to rounding.
		⁽⁸⁾	We adjust for the dilutive effect of our senior convertible notes when the effect is not the same on a GAAP and non-GAAP basis for a given period.

ABOUT NON-GAAP FINANCIAL MEASURES

The accompanying press release dated April 30, 2026 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, non-GAAP diluted net income per share, and non-GAAP diluted weighted average shares outstanding, as well as Adjusted EBITDA.

We report non-GAAP financial measures in addition to, and not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. We use these non-GAAP financial measures for financial and operational decision making and period-to-period comparisons. We believe that these non-GAAP financial measures provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by senior management in our financial and operational decision making. Our non-GAAP financial measures exclude amounts that we do not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and our senior management. While we compute non-GAAP financial measures using a consistent method from quarter to quarter and year to year, we may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures.

These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies.

We believe that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP and that these financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business.

Management believes organic revenue is a meaningful metric to investors as it provides a more consistent comparison of Dexcom's revenue to prior periods as well as to industry peers. We exclude the following items from organic revenue:

The effect of non-CGM revenue acquired or divested in the trailing twelve months; and
The effect of foreign currency fluctuations

Management believes that the presentation of operating results that exclude these items provides useful supplemental information to investors and facilitates the analysis of our core operating results and comparison of operating results across reporting periods. Management believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing our past and future operating performance.

Table D reconciles the non-GAAP financial measures included in this press release to the most directly comparable financial measures prepared in accordance with GAAP.

Our policy is to exclude the following items from non-GAAP financial measures for non-GAAP gross profit, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, and non-GAAP diluted net income per share:

Amortization of acquired intangible assets;
Business transition and related costs associated with acquisition and divestiture, integration and business transition activities, including severance, relocation, consulting, leasehold exit costs, third-party merger and acquisition costs, and other non-recurring significant items;
Income or loss from equity investments, which includes realized and unrealized gains or losses from marketable and non-marketable equity securities. These amounts may reflect changes in value due to observable price changes or impairments;
Third-party intellectual property litigation costs in connection with Dexcom's patent infringement litigation against Abbott Diabetes Care, Inc.;
Litigation settlement costs;
Gain or loss on extinguishment of debt; and
Adjustments related to taxes for the excluded items above, as well as excess benefits or tax deficiencies from share-based compensation, and the quarterly impact of other discrete items

Adjusted EBITDA excludes non-cash operating charges for share-based compensation (including equity-related charges associated with severance, restructuring, or other business transition activities), depreciation and amortization as well as non-operating items such as interest income, interest expense, gain or loss on extinguishment of debt, income or loss from equity investments, and income tax expense or benefit. For the reasons explained above, Adjusted EBITDA also excludes business transition and other significant items, litigation settlement costs, and intellectual property litigation costs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430169853/en/

INVESTOR RELATIONS CONTACT:

Sean Christensen

Senior Vice President - Finance and Investor Relations

investor-relations@dexcom.com

(858) 203-6657

MEDIA CONTACT:

James McIntosh

(619) 884-2118

Get the next $DXCM alert in real time by email

Recent Analyst Ratings for

$DXCM

Date	Price Target	Rating	Analyst
5/12/2026	$77.00	Buy	The Benchmark Company
3/24/2026	$90.00	In-line → Outperform	Evercore ISI
1/12/2026	$71.00	Equal Weight → Underweight	Barclays
12/2/2025	$75.00	Equal-Weight → Overweight	Morgan Stanley
11/25/2025	$68.00	In-line	Evercore ISI
10/21/2025	$85.00	Buy	Stifel
9/8/2025		Outperform → Perform	Oppenheimer
8/21/2025	$100.00	Buy	Argus

More analyst ratings

Dexcom Reports First Quarter 2026 Financial Results

4/30/26 4:02:00 PM ET

$DXCM

Medical/Dental Instruments

Health Care

Get the next $DXCM alert in real time by email

DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights:

Revenue grew 15% year-over-year to $1.192 billion on a reported basis and 12% year-over-year on an organic¹ basis.
U.S. revenue grew 11% and international revenue grew 26% on a reported basis and 17% on an organic¹ basis, all on a year-over-year basis.
GAAP operating income of $255.3 million or 21.4% of revenue, an increase of 850 basis points compared to the first quarter of 2025. Non-GAAP operating income* of $264.4 million or 22.2% of reported revenue, an increase of 840 basis points compared to the first quarter of 2025.

First Quarter 2026 Strategic Highlights:

Expanded the launch of Dexcom G7 15 Day CGM across all channels in the United States.
Introduced enhanced Smart Meal Logging features to the Stelo platform.
Showcased extensive clinical evidence at ATTD 2026, including one-year registry data demonstrating that Dexcom G7 delivered significant improvement in A1C for people with type 2 diabetes who are not on insulin therapy.

2026 Annual Guidance

Dexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following levels:

Revenue of $5.16 - $5.25 billion (approximately 11-13% growth)
Non-GAAP Gross Profit Margin of approximately 63-64%
Non-GAAP Operating Margin of approximately 23-23.5%
Adjusted EBITDA Margin of approximately 31-31.5%

____________________

¹ First quarter 2026 organic revenue was $1.165 billion and excludes $26.6 million of foreign exchange impact.

First Quarter 2026 Financial Results

Revenue: In the first quarter of 2026, worldwide revenue grew 15% to $1.192 billion on a reported basis, up from $1.036 billion in the first quarter of 2025.

Gross Profit: GAAP gross profit totaled $750.3 million or 62.9% of revenue for the first quarter of 2026, compared to $589.0 million or 56.9% of revenue in the first quarter of 2025.

Non-GAAP gross profit* totaled $757.4 million or 63.5% of reported revenue for the first quarter of 2026, compared to $596.2 million or 57.5% of reported revenue in the first quarter of 2025.

* See Table D below for a reconciliation of these GAAP and non-GAAP financial measures.

Conference Call

Statement Regarding Use of Non-GAAP Financial Measures

About DexCom, Inc.

Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

Category: IR

Cautionary Statement Regarding Forward Looking Statements

DexCom, Inc. Table A Consolidated Balance Sheets (In millions, except par value data) (Unaudited)
	March 31, 2026			December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$	1,118.2		$	917.7
Short-term marketable securities		1,297.0			1,081.0
Accounts receivable, net		1,088.6			1,216.1
Inventory		693.6			629.1
Prepaid and other current assets		134.3			189.4
Total current assets		4,331.7			4,033.3
Property and equipment, net		1,559.7			1,559.9
Operating lease right-of-use assets		73.1			77.4
Goodwill		24.2			24.2
Intangibles, net		62.6			70.8
Deferred tax assets		296.1			295.6
Other assets		285.9			278.7
Total assets	$	6,633.3		$	6,339.9
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities	$	2,073.9		$	1,944.0
Accrued payroll and related expenses		121.8			169.2
Short-term operating lease liabilities		20.5			21.6
Other current liabilities		7.6			7.7
Total current liabilities		2,223.8			2,142.5
Long-term senior convertible notes		1,241.8			1,240.9
Long-term operating lease liabilities		69.0			73.4
Other long-term liabilities		141.8			137.1
Total liabilities		3,676.4			3,593.9
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025		—			—
Common stock, $0.001 par value, 800.0 million shares authorized; 412.3 million and 385.9 million shares issued and outstanding, respectively, at March 31, 2026; and 410.7 million and 384.8 million shares issued and outstanding, respectively, at December 31, 2025		0.4			0.4
Additional paid-in capital		2,337.5			2,281.5
Accumulated other comprehensive income		106.2			115.0
Retained earnings		2,633.4			2,433.9
Treasury stock, at cost; 26.4 million shares at March 31, 2026 and 25.9 million shares at December 31, 2025		(2,120.6	)		(2,084.8	)
Total stockholders' equity		2,956.9			2,746.0
Total liabilities and stockholders' equity	$	6,633.3		$	6,339.9

DexCom, Inc. Table B Consolidated Statements of Operations (In millions, except per share data) (Unaudited)
	Three Months Ended March 31,
		2026		2025
Revenue	$	1,191.9	$	1,036.0
Cost of sales		441.6		447.0
Gross profit		750.3		589.0
Operating expenses:
Research and development		145.3		145.2
Selling, general and administrative		349.7		310.1
Total operating expenses		495.0		455.3
Operating income		255.3		133.7
Other income, net		14.2		20.6
Income before income taxes		269.5		154.3
Income tax expense		70.0		48.9
Net income	$	199.5	$	105.4

Basic net income per share	$	0.52	$	0.27
Shares used to compute basic net income per share		385.1		391.1
Diluted net income per share	$	0.51	$	0.27
Shares used to compute diluted net income per share		393.6		407.5

DexCom, Inc. Table C Revenue by Customer Sales Channel and Geographic Region (Dollars in millions) (Unaudited)
	Three Months Ended March 31,
	2026						2025
(In millions)	United States		International		Total		United States		International		Total
Distributor	$	796.9	$	213.4	$	1,010.3	$	720.6	$	159.4	$	880.0
Direct		35.4		146.2		181.6		29.9		126.1		156.0
Total revenue	$	832.3	$	359.6	$	1,191.9	$	750.5	$	285.5	$	1,036.0

DexCom, Inc. Table D Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures (In millions, except per share data) (Unaudited)
	Three Months Ended March 31,
		2026			2025
GAAP gross profit	$	750.3		$	589.0
Amortization of intangible assets ⁽¹⁾		7.1			7.2
Non-GAAP gross profit	$	757.4		$	596.2

GAAP operating income	$	255.3		$	133.7
Amortization of intangible assets ⁽¹⁾		8.0			7.9
Business transition and other significant items ⁽²⁾		1.1			1.0
Intellectual property litigation costs ⁽³⁾		—			0.5
Non-GAAP operating income	$	264.4		$	143.1

GAAP net income	$	199.5		$	105.4
Business transition and other significant items ⁽²⁾		1.0			1.0
Depreciation and amortization		67.1			60.0
Intellectual property litigation costs ⁽³⁾		—			0.5
Loss from equity investments		—			4.2
Share-based compensation		43.3			34.2
Interest expense and interest income		(16.4	)		(23.8	)
Income tax expense		70.0			48.9
Adjusted EBITDA	$	364.5		$	230.4

GAAP net income	$	199.5		$	105.4
Amortization of intangible assets ⁽¹⁾		8.0			7.9
Business transition and other significant items ⁽²⁾		1.1			1.0
Intellectual property litigation costs ⁽³⁾		—			0.5
Loss from equity investments		—			4.2
Adjustments related to taxes ⁽⁴⁾		7.7			8.7
Non-GAAP net income	$	216.3		$	127.7

DexCom, Inc. Table D (Continued) Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures (In millions, except per share data) (Unaudited)
	Three Months Ended March 31,
		2026			2025
GAAP net income	$	199.5		$	105.4
Interest expense on senior convertible notes, net of tax		1.6			2.9
GAAP net income used for diluted EPS, if-converted ⁽⁵⁾	$	201.1		$	108.3

Non-GAAP net income	$	216.3		$	127.7
Interest expense on senior convertible notes, net of tax		—			1.2
Non-GAAP net income used for diluted EPS, if-converted ⁽⁵⁾	$	216.3		$	128.9

GAAP diluted net income per share⁽⁵⁾	$	0.51		$	0.27
Amortization of intangible assets ⁽¹⁾		0.02			0.02
Business transition and other significant items ⁽²⁾		—			—
Intellectual property litigation costs ⁽³⁾		—			—
Loss from equity investments		—			0.01
Adjustments related to taxes ⁽⁴⁾		0.02			0.02
Impact of adjustment to GAAP diluted shares ⁽⁶⁾		0.01			—
Non-GAAP diluted net income per share ^{(5) (7)}	$	0.56		$	0.32

GAAP diluted weighted-average shares outstanding		393.6			407.5
Non-GAAP diluted weighted-average shares outstanding		385.9			399.8

Reconciliation of non-GAAP diluted weighted-average shares outstanding:
GAAP diluted weighted-average shares outstanding		393.6			407.5
Adjustment for dilutive impact of senior convertible notes due 2028 ⁽⁸⁾		(7.7	)		(7.7	)
Non-GAAP diluted weighted-average shares outstanding		385.9			399.8

		⁽¹⁾	Represents amortization of acquired intangible assets.
		⁽²⁾	For the three months ended March 31, 2026 and March 31, 2025, business transition and other significant items are primarily related to rent for vacated office space in San Diego, California.
		⁽³⁾	We have excluded third-party attorney's fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom's patent infringement litigation against Abbott Diabetes Care, Inc., as further described in the section titled "Legal Proceedings" in Dexcom's Annual Report on Form 10-K for the year ended December 31, 2024.
		⁽⁴⁾	For the three months ended March 31, 2026 and March 31, 2025, tax adjustments are primarily related to the tax effect of non-GAAP adjustments and shortfalls from share-based compensation for employees.
		⁽⁵⁾	When our senior convertible notes are dilutive on a GAAP or non-GAAP basis, net income used for calculating GAAP and non-GAAP diluted net income per share includes an interest expense add back, net of tax, under the if-converted method. In loss periods, basic and diluted net loss per share are the same since the effect of potential common shares is anti-dilutive and therefore excluded.
		⁽⁶⁾	The adjustments are for the transition from GAAP diluted net income per share to non-GAAP diluted net income per share due to our senior convertible notes.
		⁽⁷⁾	The sum of the non-GAAP per share components may not equal the totals due to rounding.
		⁽⁸⁾	We adjust for the dilutive effect of our senior convertible notes when the effect is not the same on a GAAP and non-GAAP basis for a given period.

ABOUT NON-GAAP FINANCIAL MEASURES

The effect of non-CGM revenue acquired or divested in the trailing twelve months; and
The effect of foreign currency fluctuations

Table D reconciles the non-GAAP financial measures included in this press release to the most directly comparable financial measures prepared in accordance with GAAP.

Amortization of acquired intangible assets;
Business transition and related costs associated with acquisition and divestiture, integration and business transition activities, including severance, relocation, consulting, leasehold exit costs, third-party merger and acquisition costs, and other non-recurring significant items;
Income or loss from equity investments, which includes realized and unrealized gains or losses from marketable and non-marketable equity securities. These amounts may reflect changes in value due to observable price changes or impairments;
Third-party intellectual property litigation costs in connection with Dexcom's patent infringement litigation against Abbott Diabetes Care, Inc.;
Litigation settlement costs;
Gain or loss on extinguishment of debt; and
Adjustments related to taxes for the excluded items above, as well as excess benefits or tax deficiencies from share-based compensation, and the quarterly impact of other discrete items

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430169853/en/

INVESTOR RELATIONS CONTACT:

Sean Christensen

Senior Vice President - Finance and Investor Relations

investor-relations@dexcom.com

(858) 203-6657

MEDIA CONTACT:

James McIntosh

(619) 884-2118

Get the next $DXCM alert in real time by email

Recent Analyst Ratings for

$DXCM

Date	Price Target	Rating	Analyst
5/12/2026	$77.00	Buy	The Benchmark Company
3/24/2026	$90.00	In-line → Outperform	Evercore ISI
1/12/2026	$71.00	Equal Weight → Underweight	Barclays
12/2/2025	$75.00	Equal-Weight → Overweight	Morgan Stanley
11/25/2025	$68.00	In-line	Evercore ISI
10/21/2025	$85.00	Buy	Stifel
9/8/2025		Outperform → Perform	Oppenheimer
8/21/2025	$100.00	Buy	Argus

More analyst ratings

Dexcom Reports First Quarter 2026 Financial Results

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$DXCM

Dexcom Reports First Quarter 2026 Financial Results

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$DXCM

$DXCM
Press Releases

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

$DXCM
Insider Purchases

President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

$DXCM
Analyst Ratings

The Benchmark Company initiated coverage on Dexcom with a new price target

Dexcom upgraded by Evercore ISI with a new price target

Dexcom downgraded by Barclays with a new price target

$DXCM
Insider Trading

Director Altman Steven R was granted 5,565 shares (SEC Form 4)

Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)

Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)

$DXCM
SEC Filings

DexCom Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form SD filed by DexCom Inc.

SEC Form 144 filed by DexCom Inc.

$DXCM
Leadership Updates

Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day

Dexcom Appoints Rick Osterloh to Board of Directors

Dexcom Appoints Euan Ashley to Board of Directors

$DXCM
Large Ownership Changes

SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

$DXCM
Financials